logo long.jpg
Global Eosinophilic Esophagitis Market Size to Surpass US$ 1,037.2 Million by 2028, Says Coherent Market Insights (CMI)
09 févr. 2022 09h15 HE | CMI
SEATTLE, Feb. 09, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global eosinophilic esophagitis market is estimated to be valued at US$ 138.4 million in 2021 and is expected to...
Logo on white.png
EsoCap secures new funding
18 nov. 2021 08h30 HE | EsoCap AG
EsoCap successfully closes a private financing round, with investments from existing and new investorsThe new funding was facilitated by EsoCap benefitting from a unique programme implemented by the...
Logo on white.png
EsoCap announces first patient enrolled in Phase II eosinophilic esophagitis trial
26 oct. 2021 03h00 HE | EsoCap AG
Randomized, placebo-controlled, double-blind Phase II trial to treat 42 patients ongoing in four European countries with ESO-101ESO-101, EsoCap’s lead product candidate, consists of a capsule with a...
Diagram of EsoCap application, Krause et al. 2020. © EsoCap AG
EsoCap – unique targeted application platform to treat the upper gastrointestinal tract
09 sept. 2021 03h00 HE | EsoCap AG
EsoCap’s targeted application technology drastically increases mucosal contact time and enables effective local treatment of various esophageal diseases for the first timeProof of principle in human...
PAVMEDLOGONEW15OCT2018.png
PAVmed Subsidiary Lucid Diagnostics Partners with University of Pennsylvania to Evaluate EsoCheck™ in Eosinophilic Esophagitis (EoE) Patients
02 mars 2020 09h30 HE | PAVmed Inc.
Study to assess EsoCheck as a less invasive, more efficient, and cost-effective alternative to endoscopic biopsies for rapidly emerging allergy-mediated condition which currently requires multiple and...